ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to understand physician treatment decisions in selecting specific second line treatments in pediatric ITP and to determine the effectiveness of different second line ITP treatments. Eligible patients are those ages 1-18 years who are starting on a new second line treatment for ITP, defined as any treatment other than IVIG, steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for approximately one year.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boston Children's Hospital; Boston Children’s Hospital
• Collaborator: Terrana ITP Research Fund
• Treatments: 6-Mercaptopurine; Mercaptopurine; Mycophenolate mofetil; Mycophenolic Acid; Sirolimus

Criteria

Inclusion Criteria:

• Immune Thrombocytopenia or Evans Syndrome

• Ages > 12 months to <18 years

• Starting a new second line therapy as defined as any therapy except IVIG, steroids, anti-D globulin, or aminocaproic acid

• Starting a single agent/monotherapy

Exclusion Criteria:

• Evans Syndrome with a history of or current evidence of autoimmune hemolytic anemia

• Unwillingness to be followed for 1 year

• Physician providing care is unwilling to participate

• Patient is starting multiple second line agents simultaneously